Literature DB >> 23480896

Intravascular ALK-negative anaplastic large cell lymphoma with localized cutaneous involvement and an indolent clinical course: toward recognition of a distinct clinicopathologic entity.

Ryan A Metcalf1, Sameer Bashey, Ashley Wysong, Jinah Kim, Youn H Kim, Dita Gratzinger.   

Abstract

Intravascular large T-cell or NK-cell lymphomas rarely present with cutaneous involvement. Intravascular cytotoxic T or NK lymphomas presenting in the skin (cIT/NKL) are often EBV, and reported cases follow a highly aggressive clinical course. Intravascular anaplastic large cell lymphoma (ALCL) by contrast is extraordinarily rare and, when it presents in the skin, raises the question of aggressive clinical behavior in the manner of cIT/NKL versus indolent clinical behavior in the manner of primary cutaneous ALCL. Here we describe a case of localized cutaneous intravascular anaplastic lymphoma kinase-negative ALCL (cIALCL) with a very indolent clinical course. The patient experienced a single cutaneous relapse and remains alive without disease 4 years after diagnosis. Review of the literature reveals multiple clinicopathologic differences between cIALCL and cIT/NKL: distribution (cIALCL, single skin region, P=0.021, Fisher exact test); histology (cIALCL, cohesive with necrosis, P=0.005); immunophenotype (cIALCL, strongly CD30, P=0.021; cIT/NKL, CD56 and/or EBV, P=0.003); and indolent clinical behavior with a trend toward better overall survival (P=0.067, Kaplan-Meier survival analysis). Our index case of cIALCL and 1 other tested case were immunohistochemically confirmed to be intralymphatic (contained within D2-40+vessels) as compared with the blood vessel localization of cIT/NKL. Recognition of cIALCLs as a distinct clinicopathologic entity, and in particular their distinction from aggressive, usually EBV cIT/NKLs, may be possible on the basis of a combination of clinicopathologic criteria, allowing for localized therapy in a subset of patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23480896     DOI: 10.1097/PAS.0b013e318280aa9c

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  7 in total

Review 1.  [Cutaneous lymphomas: new entities and rare variants].

Authors:  W Kempf; C Mitteldorf
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

2.  Primary effusion lymphoma presenting as a cutaneous intravascular lymphoma.

Authors:  Genevieve M Crane; Rena R Xian; Kathleen H Burns; Michael J Borowitz; Amy S Duffield; Janis M Taube
Journal:  J Cutan Pathol       Date:  2014-12-08       Impact factor: 1.587

3.  HHV-8-positive and EBV-positive intravascular lymphoma: an unusual presentation of extracavitary primary effusion lymphoma.

Authors:  Genevieve M Crane; Richard F Ambinder; Courtney M Shirley; Elliot K Fishman; Yvette L Kasamon; Janis M Taube; Michael J Borowitz; Amy S Duffield
Journal:  Am J Surg Pathol       Date:  2014-03       Impact factor: 6.394

4.  A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma.

Authors:  Wen-Tian Lyu; Qi-Bin Song; Wang Qiong; Jing Liu; Ren Yong; Feng-Tao Yi; Dong-Liang Han
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

5.  A case of exuberant cutaneous lymphomagenesis in the setting of chronic patch mycosis fungoides.

Authors:  Jason C Sluzevich; Han Tun; Demetria Strauch Jacks; Liuyan Jiang
Journal:  JAAD Case Rep       Date:  2015-01-16

6.  Recurrent systemic anaplastic large cell lymphoma: Rapid onset and resolution of cutaneous metastases.

Authors:  Jun Long; Ali Rajabi-Estarabadi; Natalie M Williams; Pooja Gurnani; Andrea Maderal; George Elgart; Keyvan Nouri
Journal:  JAAD Case Rep       Date:  2020-01-23

Review 7.  [Clinicopathological features of intravascular peripheral T-cell lymphoma].

Authors:  X Guan; Y C Yang; Y Qi; W C Gong; X Y Xu; Y L Wang; Y H Guo; Y Luo; L Sun; K Fu; B Meng
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-07-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.